How Rosuvastatin (Crestor) Affects ALT Levels

Rosuvastatin, sold under the brand name Crestor and also available as a generic oral tablet, raises alanine aminotransferase (ALT) above three times the upper limit of normal (3x ULN) in roughly 0.2% of patients at 10 mg daily, with that figure rising toward approximately 1% at the maximum 40 mg dose, based on pooled data in the FDA-approved prescribing information [1]. This kind of elevation is typically asymptomatic and reversible with dose reduction or continued monitoring. It is a distinct phenomenon from clinically apparent drug-induced liver injury, which the NIH LiverTox database and population-level studies describe as rare with rosuvastatin [3].

Why Rosuvastatin Can Raise ALT

Rosuvastatin belongs to the statin class, and all statins carry a small, dose-related tendency to raise hepatic transaminases. In the large majority of cases this reflects low-grade hepatocellular stress rather than ongoing liver injury.

The pharmacologic mechanism

Statins concentrate in the liver because that is their site of action on cholesterol synthesis. Rosuvastatin is relatively hydrophilic compared with lipophilic statins such as atorvastatin, so it depends on active hepatic uptake transporters (OATP1B1 and OATP1B3) rather than passive diffusion across cell membranes [4]. That selective uptake limits exposure to tissues outside the liver but concentrates the drug exactly where ALT originates.

The leading explanation for statin-associated ALT elevation is a mild, reversible change in hepatocyte membrane permeability that allows some ALT to leak into the bloodstream. An early analysis focused on lovastatin, sometimes cited more broadly for statin-class hepatic safety, estimated that clinically significant liver injury attributable to a statin occurs at a rate on the order of 1 per 100,000 patient-years [5]. That figure comes from a single-statin analysis published in 2002 and should be read as a general order-of-magnitude estimate for the drug class rather than a rosuvastatin-specific number.

Dose-dependent pattern

The FDA-approved prescribing information for rosuvastatin reports ALT elevations above 3x ULN in about 0.2% of patients taking 10 mg daily, rising toward roughly 1% at the maximum 40 mg dose [1]. That difference between the mid-range and maximum dose is one reason the 40 mg strength is generally reserved for patients who have not reached LDL goals on lower doses, and why a dose increase is a reasonable point to recheck liver enzymes.

How Large Is the ALT Increase in Practice?

For most patients, any ALT change on rosuvastatin is modest and clinically silent, staying within or close to the normal reference range.

Trial evidence

The JUPITER trial randomized more than 17,000 adults with LDL cholesterol below 130 mg/dL and elevated high-sensitivity CRP to rosuvastatin 20 mg or placebo. The trial reported that hepatic-related serious adverse events occurred at similarly low rates in both arms, without a clinically meaningful excess in the rosuvastatin group [6]. The exact matched percentages are sometimes quoted in secondary sources; readers who need the precise figures for a specific decision should confirm them against the original publication.

A pooled safety analysis reportedly spanning more than 16,000 rosuvastatin-treated patients across 42 clinical trials has been described as finding persistent ALT elevations above 3x ULN in roughly 0.3% of participants across the 5 to 40 mg dose range, with most elevations detected in the first 12 weeks and many resolving without any dose change; this figure should be confirmed against the primary source before being treated as definitive.

Comparing rosuvastatin to other statins

Transaminase elevation is generally described in the statin literature as a class effect rather than something unique to one molecule. A Cochrane review of statin trials used mainly to evaluate cardiovascular prevention outcomes noted that treatment-related liver enzyme elevations were uncommon across the trials it analyzed [7]. That review's primary purpose was cardiovascular outcomes, not a head-to-head hepatotoxicity comparison, so it should be treated as supportive context rather than definitive comparative data between rosuvastatin and other individual statins. A separate large head-to-head efficacy trial (STELLAR) compared rosuvastatin against atorvastatin, simvastatin, and pravastatin across matched dose ranges; it is a useful reference for relative LDL-lowering potency, but specific ALT-elevation rates by arm should be checked against the original publication before being cited as a precise number [8].

Decision Framework: What an ALT Result on Rosuvastatin Actually Means

This is not a substitute for a clinician's assessment of your specific labs, symptoms, and history. It is a way to organize the question before that conversation.

When ALT Elevation on Rosuvastatin Requires Action

The decision to reduce the dose, switch statins, or stop therapy hinges on the magnitude of the elevation, whether it persists on repeat testing, and whether symptoms are present.

The 3x ULN threshold

The 2018 ACC/AHA cholesterol guideline treats ALT above 3x ULN as the threshold warranting a clinical response, and it directs clinicians to interrupt statin therapy promptly if serious hepatotoxicity with clinical symptoms, jaundice, or elevated bilirubin develops during treatment [9]. An isolated ALT of 1.5x to 2x ULN, by contrast, is generally consistent with expected pharmacologic variability and does not by itself justify stopping the drug.

Pre-existing liver conditions

Rosuvastatin is not contraindicated in nonalcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD). A post-hoc analysis of a statin safety cohort in patients with baseline elevated transaminases attributed to fatty liver found that ALT improved over about 6 months on statin therapy [12]. That analysis was conducted with atorvastatin, not rosuvastatin, so it supports a general statin-class observation about NAFLD rather than rosuvastatin-specific proof; the underlying mechanism proposed is reduced intrahepatic fat and inflammatory signaling, which is plausible across statins but not separately confirmed for rosuvastatin in the sources reviewed here.

Active liver disease with a persistent, unexplained transaminase elevation is different and is listed as a contraindication in the rosuvastatin label. The distinction is whether the cause is known: an elevation explained by obesity-related steatosis is not the same as an unexplained one, and the former does not by itself rule out statin therapy [1].

Monitoring ALT on Rosuvastatin: Current Guidance

Recommendations have loosened over the past 15 years. Older labeling called for liver function testing at fixed intervals; current guidance is less prescriptive and focuses on baseline testing plus symptom-driven follow-up.

All major sources agree on checking ALT before starting rosuvastatin, including the 2018 ACC/AHA guideline, the ESC dyslipidemia guideline, and the FDA label [9][10][1]. During treatment, the ACC/AHA guideline does not require routine repeat testing in patients without symptoms [9]. The ESC guideline suggests rechecking hepatic enzymes 8 to 12 weeks after starting or increasing the dose, then only as clinically indicated afterward [10]. In practice many clinicians in the United States pick this up incidentally, since a comprehensive metabolic panel drawn at an annual visit includes ALT by default. After any dose increase, particularly a step up to 40 mg, checking ALT within 4 to 12 weeks is a reasonable precaution given that this is the dose range with the highest reported incidence of elevation [1].

Rosuvastatin, ALT, and Drug Interactions

Some co-administered drugs raise rosuvastatin plasma concentrations, which in turn raises the probability of ALT elevation because more drug reaches the liver.

Cyclosporine is the most significant interaction: co-administration substantially increases rosuvastatin exposure, and rosuvastatin is contraindicated in patients taking cyclosporine [1]. Gemfibrozil raises rosuvastatin exposure and requires a lower dose cap. Certain protease inhibitors used in HIV therapy (lopinavir/ritonavir, atazanavir/ritonavir) also raise rosuvastatin levels and carry FDA-recommended dose limits [1]. Anyone on these combinations should have this reviewed directly by the prescribing clinician rather than adjusted independently.

Genetic variation also plays a role. Polymorphisms in SLCO1B1, the gene encoding the OATP1B1 transporter responsible for hepatic uptake of rosuvastatin, are known to reduce hepatic uptake and increase systemic exposure in people carrying the c.521T>C variant [13]. SLCO1B1 testing is discussed more often in the context of statin-associated muscle symptoms than liver enzymes, and the exact magnitude of exposure change reported for rosuvastatin carriers varies between studies; a specific percentage should be confirmed against the primary publication before being used as a firm number.

ALT Elevation Is Not the Same as Liver Damage

This distinction matters more than any single number on a lab report.

ALT leaks from hepatocytes under many kinds of stress that have nothing to do with permanent injury, including exercise, alcohol, viral illness, obesity-related fatty liver, and some medications. Population data estimate that a meaningful share of the general adult population has an elevated ALT at any given time, with fatty liver disease the leading cause [14]. Attributing a rise automatically to rosuvastatin without considering these other causes risks stopping a medication that is reducing cardiovascular risk when the real cause lies elsewhere.

True statin-associated hepatotoxicity, including rare case reports of autoimmune hepatitis apparently triggered by statin exposure, has been documented but remains uncommon [15]. The NIH LiverTox database classifies rosuvastatin's likelihood of causing clinically apparent liver injury as low, describing such injury as very rare [3]. A separate line of post-marketing surveillance work has reported idiosyncratic statin-associated liver injury cases identified through adverse-event reporting; this kind of surveillance data can identify rare events but is not designed to give a precise incidence rate the way a controlled cohort study would, so specific incidence figures from it should be treated cautiously [15].

If rosuvastatin was stopped because of an ALT elevation that later normalized, restarting at a lower dose or switching to a different statin is a recognized approach in statin safety guidance, generally followed by rechecking ALT within a few weeks [11]. This is a clinical decision that depends on the reason therapy was stopped in the first place and should be made with the prescribing clinician, not decided independently.

Special Populations

Asian ancestry. The rosuvastatin label recommends a starting dose of 5 mg in patients of Asian descent, reflecting pharmacokinetic studies showing higher drug exposure in this population; higher exposure at any given dose raises the probability of transaminase elevation [1].

Heavy alcohol use. Regular heavy alcohol intake raises baseline ALT independently of any medication, which makes it harder to tell a statin effect apart from an alcohol effect. This does not necessarily rule out starting rosuvastatin, but it does make a baseline ALT and an earlier follow-up check more useful.

Older adults. Rosuvastatin has a renal elimination component, so declining kidney function with age can raise drug exposure. The 40 mg dose warrants more caution in older adults, and rechecking ALT after any dose increase is reasonable.

When to Seek Care Sooner

Contact the prescribing clinician promptly, without waiting for a scheduled visit, if right-upper-quadrant pain, unusual fatigue, loss of appetite, dark urine, or yellowing of the skin or eyes develops while on rosuvastatin. Seek emergency care for jaundice combined with confusion, easy bruising or bleeding, or severe abdominal pain, since these can signal acute liver injury requiring urgent evaluation rather than routine follow-up.